Angle PLC Announces Result of 2024 Annual General Meeting

Rhea-AI Summary

Angle PLC, a leading liquid biopsy company, announced that all resolutions were passed at its Annual General Meeting held on July 11, 2024. This development confirms shareholder support for the company's strategic direction and operational plans. The resolutions covered various governance and corporate matters, underscoring the company’s commitment to advancing its liquid biopsy technologies.

For more information, stakeholders can contact Angle PLC at +44 (0) 1483 343434 or Berenberg, the company's NOMAD and Broker, at +44 (0) 20 3207 7800.

Positive

• All resolutions passed at the Annual General Meeting, indicating strong shareholder support for the company's strategy.

Negative

• None.

GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix^® PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix^® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com

FAQ

What resolutions were passed at Angle PLC's 2024 Annual General Meeting?

All resolutions at Angle PLC's 2024 Annual General Meeting held on July 11, 2024, were duly passed.

How did shareholders respond to the resolutions at the 2024 Annual General Meeting?

Shareholders at Angle PLC's 2024 Annual General Meeting showed strong support by passing all resolutions.

What is the significance of all resolutions being passed at Angle PLC's AGM?

The passing of all resolutions at Angle PLC's AGM indicates unanimous shareholder endorsement of the company’s strategic and operational plans.

When was Angle PLC's 2024 Annual General Meeting held?

Angle PLC's 2024 Annual General Meeting was held on July 11, 2024.

What is Angle PLC's stock symbol on the OTCQX market?

Angle PLC's stock symbol on the OTCQX market is ANPCY.